Hospital
Brim Healthcare of Texas LLC
Brim Healthcare of Texas LLC was paid $6.26M by Medicaid between Jan 2018 and Oct 2024, across 160 billing codes. Its largest line is 99284, emergency room visit (serious) — 23% of everything it billed.
33Billing provider infoBRIM HEALTHCARE OF TEXAS LLC
TEXARKANA, TX 75501
TEXARKANA, TX 75501
33aNPI1114903523assigned 12/16/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.26M
24GClaims255,927
24DCodes billed160
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#28 of 109
Median peer was paid$1.15M
This provider vs. median5.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,332 | $370K | |
| 2019 | 39,284 | $539K | |
| 2020 | 32,660 | $507K | |
| 2021 | 37,879 | $1.20M | |
| 2022 | 43,376 | $1.45M | |
| 2023 | 46,880 | $1.45M | |
| 2024incomplete | 29,516 | $746K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 6,547 | 6,024 | $1.47M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 11,328 | 10,636 | $962K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.2% | 4,531 | 3,921 | $578K |
| 80053 | Comprehensive metabolic panel | 4.7% | 17,697 | 13,793 | $294K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 2,581 | 2,062 | $270K |
| 59025 | Fetal non-stress test | 3.8% | 1,961 | 1,118 | $235K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 3.6% | 1,246 | 970 | $224K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 2,469 | 2,087 | $211K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.5% | 5,981 | 5,564 | $155K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.4% | 2,558 | 2,419 | $152K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.1% | 2,590 | 2,128 | $132K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 22,830 | 16,954 | $131K |
148 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 7,211 | $99K |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 16,572 | $90K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 9,040 | $88K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.2% | 9,598 | $76K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 1,004 | $70K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 1,129 | $65K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 4,530 | $63K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,521 | $48K |
| 84484 | <1% | 6,624 | $41K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,004 | $40K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 937 | $38K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,826 | $36K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,138 | $32K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 879 | $29K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,101 | $29K |
| 81001 | <1% | 10,306 | $28K | |
| 86901 | <1% | 1,242 | $25K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 121 | $24K |
| 81025 | <1% | 3,165 | $22K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 525 | $21K |
| 87088 | <1% | 2,505 | $20K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,846 | $20K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 852 | $20K |
| 83690 | <1% | 3,550 | $19K | |
| 94760 | <1% | 1,427 | $19K | |
| 87400 | <1% | 2,951 | $17K | |
| 87081 | <1% | 2,575 | $17K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 517 | $17K |
| 82962 | <1% | 3,404 | $16K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 107 | $14K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,539 | $13K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 921 | $13K |
| 81003 | <1% | 4,955 | $12K | |
| 87186 | <1% | 2,126 | $11K | |
| 76801 | <1% | 324 | $11K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,736 | $10K |
| 87040 | <1% | 1,098 | $9K | |
| 85610 | <1% | 3,075 | $8K | |
| 73630 | <1% | 375 | $8K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 337 | $7K |
| 87077 | <1% | 901 | $7K | |
| 83880 | <1% | 457 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 261 | $7K |
| 83605 | <1% | 865 | $6K | |
| 87807 | <1% | 746 | $6K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 57 | $6K |
| 72141 | <1% | 34 | $6K | |
| 74018 | <1% | 325 | $6K | |
| 86710 | <1% | 313 | $6K | |
| 73610 | <1% | 404 | $5K | |
| 72100 | <1% | 277 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,512 | $5K |
| 87420 | <1% | 524 | $5K | |
| 73560 | <1% | 276 | $5K | |
| 86900 | <1% | 1,237 | $5K | |
| 85730 | <1% | 1,377 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 46 | $5K |
| 93976 | <1% | 122 | $4K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 466 | $4K |
| 80061 | Lipid panel | <1% | 967 | $4K |
| A9270 | Non-covered item or service | <1% | 7,785 | $4K |
| 83735 | <1% | 1,103 | $4K | |
| 71020 | <1% | 284 | $4K | |
| 76642 | <1% | 165 | $4K | |
| 80320 | <1% | 310 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 847 | $3K |
| 73130 | <1% | 167 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 34 | $3K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 67 | $3K |
| 87070 | <1% | 174 | $3K | |
| 84702 | <1% | 335 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,792 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 220 | $3K |
| 97161 | <1% | 98 | $3K | |
| 86850 | <1% | 436 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 182 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 160 | $2K |
| 81002 | <1% | 633 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 41 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 34 | $2K |
| 80050 | General health panel | <1% | 52 | $2K |
| 73030 | <1% | 114 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 486 | $2K |
| 82077 | <1% | 136 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 44 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 502 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 803 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 435 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 67 | $2K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 13 | $2K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 57 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 635 | $1K |
| 93017 | <1% | 75 | $1K | |
| 80305 | <1% | 107 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13 | $1K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 73 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 30 | $1K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 100 | $924.37 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,665 | $775.60 |
| 73110 | <1% | 48 | $697.77 | |
| 85027 | <1% | 157 | $644.49 | |
| 96376 | <1% | 269 | $622.03 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 19 | $594.24 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,082 | $552.25 |
| 87486 | <1% | 16 | $551.32 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,046 | $488.91 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 32 | $484.50 |
| 71010 | <1% | 73 | $461.21 | |
| 82803 | <1% | 36 | $442.08 | |
| 80143 | <1% | 28 | $385.65 | |
| 73562 | <1% | 16 | $385.00 | |
| 85007 | <1% | 116 | $361.15 | |
| 82553 | <1% | 45 | $346.08 | |
| 72040 | <1% | 19 | $326.62 | |
| 73502 | <1% | 12 | $301.28 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 388 | $293.55 |
| 87210 | <1% | 54 | $262.30 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 197 | $260.71 |
| 90715 | <1% | 14 | $259.20 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 802 | $246.16 |
| 84703 | <1% | 34 | $233.09 | |
| 82947 | <1% | 175 | $206.00 | |
| 87205 | <1% | 26 | $199.11 | |
| 97165 | <1% | 19 | $197.76 | |
| J2704 | Injection, propofol, 10 mg | <1% | 671 | $155.26 |
| 85379 | <1% | 31 | $130.77 | |
| 87158 | <1% | 33 | $126.24 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 713 | $102.46 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 88 | $101.12 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 163 | $94.74 |
| 82150 | <1% | 18 | $83.34 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 88 | $41.40 |
| 82607 | <1% | 16 | $21.52 | |
| J3490 | Unclassified drugs | <1% | 130 | $16.65 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 38 | $13.90 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 15 | $11.07 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 24 | $2.64 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 46 | $0.74 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 14 | $0.02 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 13 | $0.01 |
| 29799 | 0% | 55 | $0.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 22 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 309 | $0.00 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 18 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 166 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 14 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 45 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGILBERT, THOMAS (HOSPITAL CEO)
| Provider | Location | Paid |
|---|---|---|
| Brim Holding Company, INC. | Hope, AR | $1.79M |
| Brim Holding Company, INC. | Hope, AR | $222K |
| Brim Holding Company, INC. | Hope, AR | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.